Low-dose aspirin and low molecular weight heparin (LMWH) therapy for women having both recurrent spontaneous abortions (RSA) and primary antiphospholipid syndrome improves pregnancy outcomes significantly if initiated on the first day of the conception cycle, researchers report.
“We found that women who started the treatment on the first day of the cycle of conception had a significantly higher rate of successful outcome than those who started therapy later on,” said lead author and presenter Evangelos Ntrivalas, MD, researcher at the Center of Immunological Evaluation of RSA in Athens, Greece.
The research was reported here this week at the annual meeting of the American Society of Hematology.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!